Overview

• The VFA forecasts a 2.5% increase in revenue, 2.9% growth in production, and 1,100 additional jobs for Germany's pharmaceutical sector in 2025.
• US tariff threats have driven pharmaceutical companies to pre-stock inventories in the US, boosting exports early in the year.
• Germany exported €27 billion in pharmaceuticals to the US in 2024, representing nearly a quarter of its pharma exports, while importing €12.1 billion in finished drugs and inputs from the US.
• VFA warns that US tariffs could severely impact European pharmaceutical profitability, disrupt supply chains, and potentially lead to higher drug prices for American consumers.
• Novartis and Sanofi CEOs urge the EU to raise drug prices to US levels to support innovation and prevent further industry decline in Europe.